MK-7262 Lp(a)
a phase IIb, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-7262 coadministered with enlicitide in adults with elevated Lp(a)
- Stage
- inclusie
- Medicine
- MK-7262
- Population
- Primaire preventie coronairlijden
- Phase
- IIb
- First Patient In
- 14 September 2026
- Last Patient In
- 30 May 2027
- Last Patient Last Visit
- -
Inclusion period, 260 days remaining
Study Director
J.M. Cheng
Cardioloog
Office Contact
